- Home
- VICR vs BLTE Comparison
VICR vs BLTE Comparison
Compare VICR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VICR
- BLTE
- Stock Information
- Founded
- VICR 1981
- BLTE 2018
- Country
- VICR United States
- BLTE United States
- Employees
- VICR N/A
- BLTE N/A
- Industry
- VICR Industrial Machinery/Components
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- VICR Technology
- BLTE Health Care
- Exchange
- VICR Nasdaq
- BLTE Nasdaq
- Market Cap
- VICR 1.9B
- BLTE 2.1B
- IPO Year
- VICR N/A
- BLTE 2022
- Fundamental
- Price
- VICR $45.20
- BLTE $59.14
- Analyst Decision
- VICR Hold
- BLTE Strong Buy
- Analyst Count
- VICR 2
- BLTE 4
- Target Price
- VICR $43.00
- BLTE $96.67
- AVG Volume (30 Days)
- VICR 273.5K
- BLTE 71.8K
- Earning Date
- VICR 07-22-2025
- BLTE 08-08-2025
- Dividend Yield
- VICR N/A
- BLTE N/A
- EPS Growth
- VICR N/A
- BLTE N/A
- EPS
- VICR 0.51
- BLTE N/A
- Revenue
- VICR $369,154,000.00
- BLTE N/A
- Revenue This Year
- VICR $14.66
- BLTE N/A
- Revenue Next Year
- VICR $15.24
- BLTE N/A
- P/E Ratio
- VICR $88.07
- BLTE N/A
- Revenue Growth
- VICR N/A
- BLTE N/A
- 52 Week Low
- VICR $34.27
- BLTE $43.70
- 52 Week High
- VICR $65.70
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- VICR 45.93
- BLTE 50.31
- Support Level
- VICR $47.38
- BLTE $60.08
- Resistance Level
- VICR $49.03
- BLTE $65.30
- Average True Range (ATR)
- VICR 1.43
- BLTE 2.40
- MACD
- VICR -0.04
- BLTE 0.15
- Stochastic Oscillator
- VICR 28.41
- BLTE 56.52
About VICR Vicor Corporation
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.